Piper Jaffray Hosts 23rd Annual Healthcare Conference

Piper Jaffray (NYSE: PJC) will host its 23^rd Annual Healthcare Conference November 29–30 in New York. Industry participants and investors will hear from more than 250 influential public and private companies in the biotechnology, specialty pharmaceuticals, drug discovery, medical technology, healthcare services, and medical diagnostics and devices sectors.

"We have a longstanding commitment to the healthcare industry,” said Jeff Klinefelter, head of equity research at Piper Jaffray. "This is a time of dramatic change in healthcare driven by the pace of numerous regulatory, managed care and commercial developments. We expect investors to gain insights from leading biopharma, medical technology and healthcare services companies.”

The 23^rd Annual Piper Jaffray Healthcare Conference will feature the industry’s leading senior management teams presenting to an audience of nearly 1,500 attendees, including top institutional investors, equity portfolio managers and research analysts from the United States, the United Kingdom, Asia and Europe.

Featured companies include: Aastrom Biosciences, Inc.; Abaxis Inc.; ABIOMED, Inc.; Acceleron Pharma, Inc.; Accuray Incorporated; AcelRx Pharmaceuticals, Inc.; Achillion Pharmaceuticals, Inc.; Acorda Therapeutics, Inc.; Advisory Board Co.; Æterna Zentaris Inc.; Affymetrix, Inc.; Akorn, Inc.; Alder Biopharmaceuticals, Inc.; Alexion Pharmaceuticals, Inc.; Algeta ASA; Allergan Inc.; Allon Therapeutics, Inc.; Allscripts Healthcare Solutions, Inc.; Alnylam Pharmaceuticals, Inc.; Alphatec Holdings, Inc.; AMAG Pharmaceuticals, Inc.; AmSurg Corp.; Amylin Pharmaceuticals, Inc.; AngioChem Inc.; AngioDynamics Inc.; AngioScore, Inc.; Anthera Pharmaceuticals, Inc.; Ardea Biosciences; Arena Pharmaceuticals, Inc.; Array BioPharma Inc.; ArthroCare Corporation; Astex Pharmaceuticals, Inc.; Athersys, Inc.; AtriCure, Inc.; Avanir Pharmaceuticals; Avantis Medical Systems, Inc.; AVI Biopharma, Inc.; Baxano, Inc.; Baxter International Inc.; Becton, Dickinson and Company; Benefitfocus.com, Inc.; BG Medicine, Inc.; BioDelivery Sciences International, Inc.; BioHorizons, Inc.; bioMerieux; Boston Scientific Corporation; Cardica Inc.; Cardiocore Lab, Inc.; CardioDx, Inc.; CardioFocus, Inc.; Celgene Corporation; Cellnovo Limited; Celsion Corp.; Cepheid; Cerner Corporation; Chelsea Therapeutics International Ltd; Chimerix, Inc.; China Kanghui Holdings; Colibri Heart Valve; Complete Genomics, Inc.; Computer Programs And Systems Inc.; Conceptus, Inc.; Concert Pharmaceuticals, Inc.; CONMED Corporation; Covidien, Ltd.; CryoLife, Inc.; Curaspan Health Group, Inc.; Curis Inc.; Cutera, Inc.; CVRx, Inc.; Cyberonics, Inc.; Derma Sciences Inc.; DexCom, Inc.; DFine, Inc.; DURECT Corporation; DynaVox Inc.; e+CancerCare; EBR Systems, Inc.; Emergent BioSolutions, Inc.; Endo Pharmaceuticals Holdings Inc.; Endologix Inc.; EnteroMedics, Inc.; Exact Sciences Corporation; Exactech Inc.; Exelixis, Inc.; Flexion Therapeutics, Inc.; Fluidigm Corporation; Fresenius Medical Care AG; Genesis Biopharma, Inc.; GenMark Diagnostics, Inc.; Genomic Health, Inc.; Gen-Probe Incorporated; GetWellNetwork, Inc.; Gilead Sciences, Inc.; Greatbatch, Inc.; Hansen Medical, Inc.; HEALTHCAREfirst Inc.; Healthland, Inc.; Healthpoint Biotherapeutics; Healthways, Inc.; HeartWare International Inc.; Heat Biologics, Inc.; Hill-Rom Holdings, Inc.; HMS Holdings Corp.; Home Solutions, Inc.; Human Genome Sciences, Inc.; ICU Medical, Inc.; IDEV Technologies, Inc.; Illumina, Inc.; Impax Laboratories, Inc.; Imprivata, Inc.; Incyte Corporation; Infinity Pharmaceuticals, Inc.; Inhibitex, Inc.; Inogen, Inc.; Insite Vision Inc.; Insulet Corporation; Integra LifeSciences Holdings Corporation; IntegraMed America Inc.; Integrated Diagnostics Incorporated; IntelliPharmaCeutics International Inc.; InTouch Technologies, Inc.; Intrexon Corporation; Intuity Medical, Inc.; InVivo Therapeutics Holdings Corp.; IPC The Hospitalist Co.; IRIS International Inc.; iScience Interventional, Inc.; ISIS Pharmaceuticals Inc.; Jazz Pharmaceuticals, Inc.; Johnson & Johnson; K2M Inc.; Kips Bay Medical, Inc.; KnowledgePoint360 Group, L.L.C.; LipoScience, Inc.; Lutonix Inc.; MAKO Surgical Corp; MannKind Corp.; Masimo Corporation; MedAssets, Inc.; Medgenics, Inc.; Medicis Pharmaceutical Corp.; MEDISISS; Medivation, Inc.; MEDNAX, Inc.; MedQuist Holdings, Inc.; Medtronic, Inc.; MELA Sciences, Inc.; Merit Medical Systems, Inc.; Mesoblast Limited; Metabolex, Inc.; Metabolon, Inc.; MethylGene Inc.; Micromet, Inc.; Mindray Medical International; Morphosys AG; MWI Veterinary Supply, Inc.; Myriad Genetics, Inc.; Nanosphere, Inc.; National Research Corp.; Natus Medical Inc.; NDS Surgical Imaging, LLC; Nektar Therapeutics; NeoMend, Inc.; Neurocrine Biosciences Inc.; New American Therapeutics, Inc.; Novadaq Technologies Inc.; Novavax, Inc.; Novo Nordisk A/S; NuPathe, Inc.; NuVasive, Inc.; Nuvo Research Inc.; Nxstage Medical, Inc.; Obagi Medical Products, Inc.; Omeros Corporation; Omnicell, Inc.; OMNIlife science, Inc.; Omthera Pharmaceuticals, Inc.; Oncolytics Biotech Inc.; OncoMed Pharmaceuticals, Inc.; OptiMedica; OraSure Technologies Inc.; Orthofix International NV; Osiris Therapeutics, Inc.; Oxygen Biotherapeutics, Inc.; Pacific Biosciences of California, Inc.; Pacira Pharmaceuticals, Inc.; Pathwork Diagnostics, Inc.; PatientKeeper, Inc.; Patterson Companies Inc.; PDI, Inc.; Pearl Therapeutics, Inc.; Peregrine Pharmaceuticals Inc.; PerfectServe, Inc.; Pernix Therapeutics Holdings, Inc.; Pharmasset, Inc.; PharmAthene, Inc.; POZEN Inc.; Precision Dynamics Corporation; Precision Therapeutics, Inc.; Pulmonx Corporation; QIAGEN N.V.; Quality Systems, Inc.; Questcor Pharmaceuticals, Inc. ; Quidel Corp.; RedBrick Health Corporation; Regeneron Pharmaceuticals Inc.; Regulus Therapeutics, LLC; ResMed Inc.; REVA Medical, Inc.; Revance Therapeutics, Inc.; Rigel Pharmaceuticals; Rochester Medical Corp.; Salix Pharmaceuticals, Ltd.; Santarus Inc.; SANUWAVE Health, Inc.; SciClone Pharmaceuticals, Inc.; Seattle Genetics Inc.; Sequenom Inc.; Shanghai Kinetic Medical Co., Ltd.; Signature Diagnostics AG; Sinovac Biotech Ltd.; Sonitus Medical Inc.; St. Jude Medical, Inc.; STAAR Surgical Company; Steris Corp.; Sunshine Heart Inc.; superDimension, Ltd.; SuperNova Diagnostics, Inc.; SurModics Inc.; Suture Express, Inc.; Symmetry Medical Inc.; Team Health Holdings, Inc.; TearLab Corporation; TEI Biosciences, Inc.; Tengion, Inc.; Teva Pharmaceutical Industries Limited; The Spectranetics Corporation; Theravance Inc.; Thoratec Corporation; Topera, Inc.; Tornier N.V.; TranS1 Inc.; Tranzyme, Inc.; Trius Therapeutics, Inc.; TyRx Pharma, Inc.; Ulthera Inc.; UnitedHealth Group, Inc.; Vascular Solutions Inc.; VBI Vaccines; VCA Antech, Inc.; Vertex Pharmaceuticals Inc.; VertiFlex, Inc.; Vertos Medical, Inc.; ViroPharma Incorporated; Volcano Corporation; Watson Pharmaceuticals, Inc.; Wright Medical Group, Inc.; XDx, Inc.; XenoPort, Inc.; Zalicus Inc.; ZIOPHARM Oncology, Inc.; Zogenix, Inc.; Zoll Medical Corp.

Company and investor participation in the Piper Jaffray Healthcare Conference is by invitation only. Clients interested in attending should contact their Piper Jaffray representative. General and research-related media inquiries should be directed to AnalystMediaRelations@pjc.com. Investment banking-related media inquiries should be directed to Julie Lewis at julie.a.lewis@pjc.com.

About Piper Jaffray

Piper Jaffray is a leading middle-market investment bank and asset management firm serving clients in the U.S. and internationally. Our proven advisory teams combine deep product and sector expertise with ready access to global capital. Founded in 1895, the firm is headquartered in Minneapolis with offices across the United States and in Hong Kong, London and Zurich. www.piperjaffray.com

Since 1895. Member SIPC & NYSE.
© 2011 Piper Jaffray & Co.